{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:46:26Z","timestamp":1761518786743},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1053\/j.seminoncol.2004.09.023","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"23-30","source":"Crossref","is-referenced-by-count":10,"special_numbering":"S12","title":["Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy"],"prefix":"10.1053","volume":"31","author":[{"given":"Harold A.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl","key":"10.1053\/j.seminoncol.2004.09.023_bib1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib2","series-title":"Diseases of the Breast","first-page":"407","article-title":"Natural history of breast cancer","author":"Hellman","year":"2000"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/107327480200900603","article-title":"Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer","volume":"9","author":"Minton","year":"2002","journal-title":"Cancer Control"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0140-6736(86)92131-8","article-title":"Mechanism of action of adjuvant chemotherapy in early breast cancer","volume":"2","author":"Padmanabhan","year":"1986","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2004.09.023_bib6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0960-9776(03)80158-3","article-title":"Challenges in the endocrine management of breast cancer","volume":"12","author":"Mouridsen","year":"2003","journal-title":"Breast"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1023\/A:1021888317011","article-title":"The ATAC (\u2019Arimidex\u2019, Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - Updated efficacy results based on a median follow-up of 47 months","volume":"77","author":"Buzdar","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42\u2032446, a new, potent, heterocyclic bisphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"J Bone Mineral Res"},{"issue":"suppl 2","key":"10.1053\/j.seminoncol.2004.09.023_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2165\/00024669-200302030-00006","article-title":"Spotlight on zoledronic acid in the management of bone metastases and hypercalcemia of malignancy","volume":"2","author":"Wellington","year":"2003","journal-title":"Am J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib17","series-title":"GLOBOCAN 2000","author":"Ferlay","year":"2001"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib18","series-title":"Cancer","first-page":"2713","article-title":"Metastatic cancer to the bone","author":"Brown","year":"2001"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib21","first-page":"3383","article-title":"Efficacy of pamidronate in breast cancer with bone metastases","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib22","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib23","series-title":"Cancer","first-page":"2633","article-title":"Metabolic emergencies","author":"Warrell","year":"2001"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy","volume":"19","author":"Major","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib25","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/annonc\/mdh111","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"15","author":"Westermann","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib28","first-page":"388b","article-title":"An assessment of patient preferences for intravenous zoledronic acid or pamidronate in patients commencing bisphosphonate therapy for malignant disease in bone","volume":"100","author":"Joseph","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2004.09.023_bib30","doi-asserted-by":"crossref","first-page":"372s","DOI":"10.1158\/1078-0432.CCR-031210","article-title":"Prevention strategies with aromatase inhibitors","volume":"10","author":"Goss","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.09.023_bib31","first-page":"S27","article-title":"Effect of anastrozole on bone mineral density","volume":"82","author":"Howell","year":"2003","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib32","first-page":"225","article-title":"A pilot prevention study of the aromatase inhibitor letrozole","volume":"69","author":"Harper-Wynne","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib34","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib35","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1210\/jc.85.5.1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib37","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1210\/jc.79.6.1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.seminoncol.2004.09.023_bib38","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bone.2004.01.008","article-title":"Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis","volume":"34","author":"Recker","year":"2004","journal-title":"Bone"},{"issue":"suppl 1","key":"10.1053\/j.seminoncol.2004.09.023_bib39","first-page":"S31","article-title":"Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (+\/\u2212 zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer","volume":"76","author":"Gnant","year":"2002","journal-title":"Breast Cancer Res Treat"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404004208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775404004208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:28:51Z","timestamp":1554337731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775404004208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":39,"alternative-id":["S0093775404004208"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2004.09.023","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]}}}